.webp?width=217&height=60&name=Screenpoint-Med%20(1).webp "Screen Point Medical")
%20(1).png)
MASAI RCT: 12% reduction in interval cancer rate using Transpara
.png)
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
.png)
ScreenPoint Medical Enables Transpara® Breast AI within Precision Imaging Network, part of Microsoft for Healthcare
Discussing AI findings in the patient record
Dr. Rachel Brem explores how providers might think about AI findings - including breast imaging - in the patient record and where she landed on the topic.
.png)
Breast AI + Tomosynthesis: The Perfect Match
Dr. Ben Pettus discusses how Breast AI complements digital breast tomosynthesis, making radiologists both more accurate and more efficient.
%20(1).png)
What's the best AI for breast cancer detection (for your screening program)?
Considering your options for breast cancer AI can be difficult; this guide and vendor comparison chart makes it simpler to differentiate and decide.
What MASAI reinforces about AI in USA screening mammography
What can results from the MASAI randomised controlled trial tell us about the state of breast AI research in screening mammography in the United States?
.png)
Interview: The Imaging Wire highlights MASAI findings
Brian Casey of The Imaging Wire interviews researcher Jessie Gommers on the latest results from the MASAI randomised controlled trial in breast cancer AI.
What studies showed us about Transpara in 2025
Highlights from peer-reviewed research on Transpara Breast AI published in 2025 on increasing breast cancer detection and reducing radiology workload.